ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ РАСТВОРИМЫХ РЕЦЕПТОРОВ К ФНО ? В ТЕРАПИИ ЮВЕНИЛЬНЫХ АРТРИТОВ
Аннотация
Ключевые слова: дети, ювенильный ревматоидный артрит, лечение, этанерцепт.
(Вопросы современной педиатрии. 2008;7(5):51-56)
Об авторах
Е.И. АлексееваРоссия
С.И. Валиева
Россия
Р.В. Денисова
Россия
Т.М. Бзарова
Россия
Список литературы
1. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: ВЕДИ. 2007. 368 с.
2. Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей. Качество жизни. Медицина. 2008; 1: 14–17.
3. Яковлева Л.В. Психологические особенности личности детей с ювенильным ревматоидным артритом. Российский педиатрический журнал. 1998; 6: 20–21.
4. Huygen A.C., Kuis W., Sinnema G. Psychological, behavioral and social adjustment in children and adolescents with juvenile chronic arthritis. Ann. Rhem. Dis. 2000; 59 (4): 276–282.
5. Яковлева А.А., Краснова К., Ченчикова Э. Д-пенициламин в терапии ревматоидного артрита у детей. Материалы международного научного симпозиума по ревматологии. Тбилиси. 1980. C. 120–121.
6. Долгополова А.В., Бисярина В.П., Алексеев Л.С. и др. Разработка критериев ранней диагностики ювенильного ревматоидного артрита (ЮРА). Вопросы ревматологии. 1979; 4: 3–7.
7. Яковлева А.А. Некоторые соображения о применении цитотоксических препаратов при ревматоидном артрите у детей. Педиатрия. 1981; 2: 27–33.
8. Кузьмина Н.Н., Шахбазян И.Е., Брюэр Э. и др. Терапевтическая эффективность ауронофина при ювенильном ревматоидном артрите по результатам советско-американского исследования. Тезисы докладов Всесоюзной конференции ревматологов. М. 1988. С. 1.
9. Шахбазян И.Е. О внутрисуставном введении гидрокортизона при инфекционном неспецифическом полиартрите у детей. Тезисы докладов научной конференции I ММИ им. И.М. Сеченова. М. 1966.
10. Жолобова Е.С., Шахбазян И.Е. Внутрисуставное применение дипроспана у больных с ювенильным ревматоидным артритом. Детская ревматология. 1996; 3: 7–10.
11. Алексеева Е.И. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Автореф. дис. … докт. мед. наук. М. 2000. 48 с.
12. Алексеева Е.И., Валиева С.И., Апаева Д.В. Эффективность и безопасность комбинированной иммуносупрессивной терапии циклоспорином А и метотрексатом у больных тяжелым ювенильным ревматоидным артритом. Вопросы современной терапии. 2006; 5 (2); 19–27.
13. Ruperto N., Nikishina I.P., Pachanov E.D. et al. A randomized double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005; 52: 563–572.
14. Алексеева Е.И., Шахбазян И.Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. М.: Novartis. 2002. Р. 31–36.
15. Lomater C., Gerloni V., Gattinara M. et al. Systemic onset juvenile rheumatoid arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.
16. Minden K., Niewerth M., Listing J. et al. Long-term outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2392–2401.
17. Foster H.E., Marshall N., Myers A. et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003; 48: 767–775.
18. El-Gabalawy H.S., Lipsky P.E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004; 4 (Suppl. 2): 297–301.
19. Woo P., Wilkinson N., Prieur A.M. et al. Open label phase 2 trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of efficacy of IL-6 receptor blocade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 2005; 7: 1281–1288.
20. Woo P. The cytokine network in juvenile chronic arthritis. Rheum. Dis. Clin. North. Am. 1997; 23 (3): 491–498.
21. Sewell E., Trentham D. Pathogenesis of rheumatoid arthritis. Lancet. 1993; 341 (8840): 283–286.
22. Moore T.L Immunopathogenesis of juvenile rheumatoid arthritis. Curr. Opin. Rheumatol. 1999; 11 (5): 377–383.
23. Miossec P. The role of the Thl and Th2 dichotomy in the pathogenesis of juvenile chronic arthritis. Rev. Rhum. 1997; 64 (Suppl. 10): 138–139.
24. Aarvak Т., Chabaud M., Kallberg E. et al. Change in theThl/Th2 phenotypeof memory T-cell clones from rheumatoid arthri¬tis synovium. Scan. J. Immunol. 1999; 50 (1): 1–9.
25. Mangge H., Kenzian H., Gallistl S. et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheumatism. 1995; 38 (2): 211–220.
26. Feldman M., Brennan F., Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.
27. Dinarello C.A., Moldawer L.L. Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primer for clinicians. 2nd ed. NY: Amgen Inc. 2000. 282 p.
28. Tracey K.J., Beutler B., Lowry S.F. et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986; 234 (4775): 470–474.
29. Tracey K.J., Fong Y., Hesse D.G. et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteriemia. Nature. 1987; 330 (6140): 662–664.
30. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.
31. Dinarello CA, Moldawer L.L. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. A primar for clinicians. Third edition. NY: Amgen Inc. 2002. 351 p.
32. Georgopoulos S., Plows D., Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 1996; 46 (2): 86-97.
33. Williams R.O., Feldmann M., Maini R.N. Anti–tumor necrosis factor ameliorates joint diseasae in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 1992; 89: 9784–9788.
34. Williams R.O. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol. Biol. 2006; 361: 265–284.
35. Barrera P., Th. Boerbooms A.M., Janssen E.M. et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor , and interleukin 6 levels in rheumatoid arthritis. Arthritis Rheum. 1993; 36: 1070–1079.
36. Beckman J.C., Caldwell D.S., Peterson B.L. et al. Disease severity in rheumatoid arthritis: relationship of plasma tumor necrosis factor–, soluble interleukin-2 receptor, soluble XD4/CD8 ratio, neopterin, and fibrin D–dimer to traditional severity and functional measures. J. Clin. Immunol. 1992; 12 (5): 353–361.
37. Chu C.Q., Field M., Feldman M., Maini R.N. Localization of tumor necrosis factor in synovial tissues and at cartilage pannus junction in patients with rheumatoid. Arthritis Rheum. 1991; 34 (9): 1125–1132.
38. Cope A., Aderka D., Doherty M. et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic disease. Arthritis Rheum. 1992; 35 (10): 1160–1169.
39. Heilig B., Wermann M., Gallati H. et al. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin. Invest. 1992; 70: 22–27.
40. Roux-Lombard P., Punzi L., Hasler F. et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum. 1993; 36: 485–489.
41. Насонов Е.Л. Фактор некроза опухоли–ᾳ — новая мишень для противовоспалительной терапии ревматоидного артрита. Клин. фармакол. и терапия. 2001; 1: 64–70.
42. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. New Engl. J. Med. 2004; 350: 2167–2179.
43. Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. РМЖ. 2001; 9: 7–9.
44. Lorenz H.M., Kalden J.R. Perspectives for TNFa targeting therapies. Arthritis Research. 2002; 4: 17–24.
45. Kalden J.R. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Res. 2002; 4: 34–40.
46. Garrison L., McDonnell N.D. Etanercept. Therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999; 58: 165–169.
47. Goldenberg M.M. Etanercept, a novel drug for the treatment of patients with Clincher severe, active rheumatoid arthritis. Clin. Ther. 1999; 21: 75–87.
48. Moreland L.W., Margolies G., Heck L.W. et al. Recombinant soluble tumor necrosis factor receptor fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 1996; 23: 1849–1855.
49. Moreland L.W., Scott M.D., Baumgarther W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) Fc fusion protein. New Engl. J. Med. 1997; 337: 141–147.
50. Moreland L.W., Schiff M.H., Baumgarthner S.W. et al. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 1999; 130: 478–486.
51. Breedveld F., Emery P., Ferraccioli G. et al. Clinical response and remission at 12, 24, and 52 weeks with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis in the COMET trial. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 320.
52. Emery P., Breedveld F., Hall S. et al. Clinical remission, radiographic non-progression, and normalized function with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis: 1-year results of the COMET trial. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 50.
53. Brandt J., Kariouzov A., Listing J. et al. Six months results of a German double-blind placebo controlled, phase-III clinical trial of Etanercept in active ankylosing spondylitis. Arthritis Rheum. 2002; 46: 429.
54. Calin A., Dijkmans B., Emery P. et al. Assessments of disease activing and functionality by Enbrel-treated ankylosing spondylitis patients in multicenter, placebo controlled trial. Arthritis Rheum. 2003; 48: 172.
55. Davis J.C., van der Heijde D., Braun J. et al. Etanercept (Enbrel) improves signs and symptoms of ankylosing spondylitis: results of a phase 3 multicenter clinical trial. Ann. Rheum. Dis. 2003; 62: 65.
56. Gorman J.D., Sack K.E., Davis J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. New Engl. J. Med. 2002; 346: 1349–1356.
57. Van der Heijde D., Dougados M., Davic J.C. et al. The effects of etanercept on patient-reported outcomes for subjects with ankylosing spondylitis. Arthritis Rheum. 2003; 48: 174.
58. Martin Mola, S. van der Linden, C. Wishneski et al. Long term efficacy and safety, including patient-reported outcomes, with etanercept for 5 years in ankylosing spondylitis. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 510.
59. D'Angelo S., Cutro M.S., Lubrano E. et al. Combination therapy with cyclosporin and etanercept in patients with psoriatic arthritis. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 524.
60. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2008.
61. Prince F.H., Twilt M., Ten Cate R. et al. Long term follow up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. 2008.
62. Nielsen S., Ruperto N., Gerloni V. et al.. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2008; 26 (4): 688–692.
63. Lovell D.J., Reiff A., Ilowite N.T. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.
64. Simonini G., Giani T., Stagi S. et al. Bone status over 1 yr. of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford). 2005; 44 (6): 777–780.
65. Robinson R.F., Nahata M.C., Hayes J.R. et al. Quality of life measurements in juvenile rheumatoid arthritis patients treated with etanercept. Clin. Drug Investig. 2003; 23 (8): 511–518.
66. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.
67. Kimura Y., Pinho P., Walco G. et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 2005; 35: 935–942.
68. Prahalad S., Bone K.E., Dickens D. et al. Etanercept in the treatment of macrophage activation syndrome. J. Rheumatol. 2001; 28: 2120–2124.
69. Dixon W.G., Hyrich K.L., Watson K.D. et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti–TNF therapy: results from the BSR biologics register (BSRBR). Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 178.
70. Fouache D., Goëb V., Ménard J. et al. Paradoxal adverse events under anti-TNFalpha therapy in spondylarthritides: significant association between infliximab and new cases of dermatological events. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 386.
71. Askling J., Raaschou P., van Vollenhoven R. et al. Anti-TNF therapy in RA and cancer risk: relation to duration of follow-up, cumulative treatment, and therapeutic response. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 52.
72. Gottlieb A.B., Gordon K.B., Giannini E.H. et al. Malignancies from patients receiving etanercept across approved indications. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 322.
73. Mariette X., Tubach F., Ravaud P. et al. Patients on anti-TNF have an increased risk of lymphoma compared with the general population. results of the French 3-year prospective ratio observatory. Ann. Rheum. Dis. 2008; 67 (Suppl. 2): 323.
Рецензия
Для цитирования:
Алексеева Е., Валиева С., Денисова Р., Бзарова Т. ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ РАСТВОРИМЫХ РЕЦЕПТОРОВ К ФНО ? В ТЕРАПИИ ЮВЕНИЛЬНЫХ АРТРИТОВ. Вопросы современной педиатрии. 2008;7(5):51-56.
For citation:
Alexeeva E., Valieva S., Denisova R., Bzarova T. ASPECTS OF TREATMENT OF JUVENILE ARTHRITIS WITH SOLUBLE RECEPTORS TO TNF. Current Pediatrics. 2008;7(5):51-56.
Послать статью по эл. почте 
